Katherine Stueland sold $1.6M of WGS
CHIEF EXECUTIVE OFFICER at GeneDx Holdings Corp.. 10,857 shares at an average of $143.89, traded Dec 16, 2025, filed Dec 18, 2025.
Score components
- +25RoleCEO
- +25Trade size$1.6M at market
- +10Share of holdings soldSold 43% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001689575-25-000017, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 16, 2025 | MOption exercise Class A Common Stock | +18,750 | $0.00 | $0 | 25,094 | Dec 18, 2025 |
| Dec 16, 2025 | SOpen-market sale Class A Common Stock | -369 | $138.93 | $51k | 24,725 | Dec 18, 2025 |
| Dec 16, 2025 | SOpen-market sale Class A Common Stock | -1,031 | $140.08 | $144k | 23,694 | Dec 18, 2025 |
| Dec 16, 2025 | SOpen-market sale Class A Common Stock | -2,679 | $141.20 | $378k | 21,015 | Dec 18, 2025 |
| Dec 16, 2025 | SOpen-market sale Class A Common Stock | -604 | $142.12 | $86k | 20,411 | Dec 18, 2025 |
| Dec 16, 2025 | SOpen-market sale Class A Common Stock | -940 | $144.27 | $136k | 19,471 | Dec 18, 2025 |
| Dec 16, 2025 | SOpen-market sale Class A Common Stock | -1,628 | $145.36 | $237k | 17,843 | Dec 18, 2025 |
| Dec 16, 2025 | SOpen-market sale Class A Common Stock | -1,970 | $146.93 | $289k | 15,873 | Dec 18, 2025 |
| Dec 16, 2025 | SOpen-market sale Class A Common Stock | -932 | $148.55 | $138k | 14,941 | Dec 18, 2025 |
| Dec 16, 2025 | SOpen-market sale Class A Common Stock | -274 | $149.20 | $41k | 14,667 | Dec 18, 2025 |
| Dec 16, 2025 | SOpen-market sale Class A Common Stock | -74 | $150.75 | $11k | 14,593 | Dec 18, 2025 |
| Dec 16, 2025 | SOpen-market sale Class A Common Stock | -356 | $140.95 | $50k | 14,237 | Dec 18, 2025 |
| Dec 16, 2025 | MOption exercise Restricted Stock Unitderivative | -18,750 | $0.00 | $0 | 93,750 | Dec 18, 2025 |
Related signals
Other insiders at GeneDx Holdings Corp. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $364k 3,728 shares | -8% | |
| 43Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $1.0M 10,501 shares | -8% | |
| 25Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $108k 1,285 shares | -3% | |
| 32Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $311k 3,692 shares | -3% | |
| 20Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $31k 372 shares | -1% | |
| 39Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $557k 8,818 shares | -20% | |
| 53Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $3.0M 46,933 shares | -34% | |
| 37Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $438k 5,706 shares | -17% | |
| 48Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $1.3M 17,179 shares | -23% | |
| 25Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $111k 1,280 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.